GlucoTrack

GCTK

Market cap $6.79M

Overview Fund Activity

7.55 USD

-0.35

4.43%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

7.54

-0.01

0.13%

1 day

-4.43%

5 days

62.37%

1 month

31.99%

3 months

24.38%

6 months

-66.17%

Year to date

-98.02%

1 year

-99.78%

5 years

-99.97%

10 years

-99.97%

About: GlucoTrack Inc is a medical device company. It is focused on defining novel approaches that make diabetes management more accurate and convenient for daily living. The company has developed the GlucoTrack model that measures real-time blood glucose levels. The Company is developing an long-term implantable continuous blood glucose monitoring (CBGM) system, built on healthcare technologies. It is designed to meet the critical needs of insulin-dependent individuals or those at risk of hypoglycemia in the U.S.

Employees: 11

Healthcare Medical Instruments & Supplies

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

150% more funds holding

Funds holding: 4 [Q1] → 10 (+6) [Q2]

150% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 4

0.04% less ownership

Funds ownership: 0.06% [Q1] → 0.02% (-0.04%) [Q2]

42% less capital invested

Capital invested by funds: $69.8K [Q1] → $40.6K (-$29.2K) [Q2]

See Fund Rankings

Financial journalist opinion

Glucotrack to Participate in the Q3 Virtual Investor Summit

RUTHERFORD, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that management will present and participate in one-on-one meetings with investors at the Q3 Virtual Investor Summit, being held on September 16-17, 2025.

Glucotrack to Participate in the Q3 Virtual Investor Summit

Glucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025

Glucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Glucotrack Expands Clinical Advisory Team Appointing David S. Hirsh, MD as Medical Director, Cardiology

Experienced cardiac electrophysiologist joins Glucotrack's growing clinical advisory team as the Company advances its long-term CBGM through critical clinical milestones Experienced cardiac electrophysiologist joins Glucotrack's growing clinical advisory team as the Company advances its long-term CBGM through critical clinical milestones

Glucotrack Expands Clinical Advisory Team Appointing David S. Hirsh, MD as Medical Director, Cardiology

Glucotrack to Exhibit at 2025 Association of Diabetes Care and Education Specialists Annual Meeting

Company to present endocrinologist perspectives on implantable CBGM technology as it advances toward US pilot study Company to present endocrinologist perspectives on implantable CBGM technology as it advances toward US pilot study

Glucotrack to Exhibit at 2025 Association of Diabetes Care and Education Specialists Annual Meeting

Glucotrack Announces Repurchase of Series A Warrants

RUTHERFORD, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has successfully repurchased over 90% of its outstanding Series A Warrants from warrant holders on June 30, 2025.

Glucotrack Announces Repurchase of Series A Warrants

Why Is This Nano-Cap Glucotrack Stock Trading Higher On Wednesday?

Glucotrack Inc. GCTK stock traded higher on Wednesday, with a session volume of 15.91 million compared to the average of 81.7K, according to data from Benzinga Pro.

Why Is This Nano-Cap Glucotrack Stock Trading Higher On Wednesday?

Glucotrack and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor at American Diabetes Association's 85th Scientific Sessions

RUTHERFORD, N.J. and STOCKHOLM, June 25, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced results from its completed first-in-human clinical study presented at the American Diabetes Association's (ADA) 85th Scientific Sessions, which took place June 20-23, 2025, in Chicago.

Glucotrack and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor at American Diabetes Association's 85th Scientific Sessions

Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements

1-for-60 reverse stock split to become effective as of the opening of trading on June 16, 2025 Rutherford, NJ, June 12, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will effect a 1-for-60 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common stock par value $0.001 per share (the “Common Stock”), effective with the opening of trading on Monday, June 16, 2025. Glucotrack's Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “GCTK”.

Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements

Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association's 85th Scientific Sessions

Glucotrack to present on next-generation continuous blood glucose monitoring technology in Innovation Hub Poster presentation to highlight insights on safety and performance data from direct blood glucose measurement technology RUTHERFORD, N.J., June 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced it will present safety and performance data from its first-in-human trial of its implantable continuous blood glucose monitoring (CBGM) system.

Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association's 85th Scientific Sessions

Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD

Experienced medical device executive with deep expertise in implantable technologies joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology Experienced medical device executive with deep expertise in implantable technologies joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology

Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD

See News Rankings

Charts implemented using Lightweight Charts™